Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06672237 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06672237 · ClinicalTrials.gov record · last posted 2026-04-16

A Phase 3 Study of NTLA-2001 in ATTRv-PN

StatusRecruiting
PhasePhase 3
Started2024-11-22
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.

Amendment record 18 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 18 times since 2024-11-01; most recent amendment 2026-04-13. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-04-13
Status change Active, Not Recruiting→Recruitingv18
2025-11-24
Status change Recruiting→Active, Not Recruitingv17
2024-11-21
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06672237
Lead Sponsor Intellia Therapeutics
Collaborators: Regeneron Pharmaceuticals
Conditions Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease, Neurodegenerative Disease, Hereditary, Neurodegenerative Diseases, Neuromuscular Diseases, Nerve Disorders, Nervous System Disease +12 more
Enrollment 60 participants
Start Date 2024-11-22
Primary Completion 2027-07 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-16